Chosa Oncology, Danish -Swedish biotechnology company, has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the companion diagnostic (DRP) tool detecting patients who benefits the most of the cisplatin treatment. The recently achieved clinical phase 2b results mean that the Company is now gearing up the business development activities to find partners for partnership or trade deal.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Buhl Krone Holding ApS | 22,00 | 22,00 | 2024-12-23 |
| Claus Frisenberg Pedersen | 11,68 | 11,68 | 2023-01-18 |
| IPO Nordic Fund A/S | 8,36 | 8,36 | 2024-12-23 |
| Smerud Medical Research International AS | 7,48 | 7,48 | 2024-12-23 |
| Rutger Arnhult | 5,48 | 5,48 | 2024-12-23 |
| Nels Holding Aps | 4,00 | 4,00 | 2024-12-23 |
| Lh|Lh Invest Aps | 2,97 | 2,97 | 2024-12-23 |
| Karsgaard Holding Ostervra Aps | 2,36 | 2,36 | 2024-12-23 |
| Sorgenfri Nr. 1 A/S | 2,17 | 2,17 | 2024-12-23 |
| Rq Solutions Aps | 1,87 | 1,87 | 2024-12-23 |
2025-05-30 Delårsrapport 2025-Q1
2025-06-13 Årsstämma 2024
2025-08-29 Delårsrapport 2025-Q2
2025-11-28 Delårsrapport 2025-Q3
